FindTrial
Sign In

Study on improving the accuracy of bone marrow invasion in diffuse large B-cell lymphoma based on AI cell morphology

Study on improving the accuracy of bone marrow invasion in diffuse large B-cell lymphoma based on AI cell morphology

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200059165
Enrollment
Unknown
Registered
2022-04-26
Start date
2022-05-01
Completion date
Unknown
Last updated
2024-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse large B-cell lymphoma

Interventions

Gold Standard:Bone marrow biopsy and immunohistochemical staining confirmed diffuse large B-cell lymphoma infiltration.
Index test:The sensitivity, specificity and accuracy of AI in lymphoma cell recognition were evaluated.

Sponsors

Chongqing University Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 80 Years

Inclusion criteria

Inclusion criteria: Diffuse large B-cell lymphoma was diagnosed by pathology, and the bone marrow cell morphology, bone marrow histopathology and flow cytometry were completed.

Exclusion criteria

Exclusion criteria: 1. Hematological malignancies such as leukemia and myeloma confirmed by histopathology; 2. Non-hematopoietic tumors; 3. Clinicopathological data were incomplete.

Design outcomes

Primary

MeasureTime frame
accuracy;—

Countries

China

Contacts

Public ContactYang Zailin

Chongqing University Cancer Hospital

804728092@qq.com+86 18523410193

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026